



About Arch Pharmalabs Limited Unlisted Equity

ARCH PHARMALABS LIMITED is a pharmaceutical company with two business segments: Products and Services. Our Products business includes manufacturing and distribution of APIs and intermediates to innovative and generic pharmaceutical companies in domestic and international markets including regulated markets.

The company currently has seven manufacturing facilities across India. All seven production facilities are multipurpose facilities with reactor capacity of 1000KL and above.

Manufacturing Facilities:

1. Gurgaon, Vitalife Location
2. Hyderabad, Melben Location
3. Hyderabad, Watsol Location
4. Mumbai, Badlapur Location
5. Oncology location, Tarapur
6. Taloha location, Mumbai
7. Dombivli location, Mumbai

Key Leaders:

Mr. Ajit Kamath (51) is the Executive Chairman and Managing Director of the Company and was appointed on January 1, 2001. He holds a Bachelor of Commerce degree from Mumbai University and has 19 years of experience in the pharmaceutical industry. Prior to joining the Company, he worked with CEAT Financial Services Limited and co-founded Arch Commerz Private Limited. He played a key role in the company's acquisitions, including the Gurgaon unit in December 2004, and has played a key role in business strategy and development.

Rajendra Kaimal (48) is our Managing Director and was first appointed on November 1, 2003. He holds a Bachelor's in Commerce from Mumbai University, a Master's in Business Administration from Narsee Monjee Institute, and is a Certified Cost Accountant. As co-founder of Arch Commerz Private Limited, he has 18 years of experience in the pharmaceutical industry. Rajendra oversees the company's commercial activities, including purchasing and export functions, and coordinates day-to-day activities across all manufacturing facilities.

Issues Sharing to Nipro Pharma Packaging

On March 8, 2023, the Company issued 45,57,637 equity shares of Rs. 328 per share to Nipro PharmaPackaging India Private Limited as non-monetary consideration. h. By converting financial obligations.

Fundamentals

Fundamentals			
Arch Pharmalabs	90 Per Equity Share	Market Cap (in cr.)	1330.08
Unlisted Shares Price		P/E Ratio	10.9
Lot Size	250 Shares	P/B Ratio	1.59
52 Week High	-	Debt to Equity	1.01
52 Week Low	-	ROE (%)	14.57
Depository	NSDL & CDSL	Book Value	53.52
PAN Number	AACCM0306Q	Face Value	10
ISIN Number	INE182F01017		

Financials (Figures in cr)

P&L Statement			
P&L Statement	2021	2022	2023
Revenue	706	1309	1341
Cost of Material Consumed	444	1052	1062
Gross Margins	37.11	19.63	20.81
Change in Inventory	21	-68	-37
Employee Benefit Expenses	74	75	69
Other Expenses	892	73	67
EBITDA	-725	177	180
OPM	-102.69	13.52	13.42
Other Income	2853	-1	1
Finance Cost	231	98	35
D&A	28	25	23
EBIT	-753	152	157
EBIT Margins	-106.66	11.61	11.71
PBT	1869	52	122
PBT Margins	264.73	3.97	9.1
Tax	0	0	0
PAT	1869	52	122
NPM	264.73	3.97	9.1
EPS	123.03	3.42	7.8
Financial Ratios	2021	2022	2023
Operating Profit Margin	-102.69	13.52	13.42
Net Profit Margin	264.73	3.97	9.1
Earning Per Share (Diluted)	123.03	3.42	7.8

Balance Sheet			
Assets	2021	2022	2023
Fixed Assets	926	879	820
CWIP	22	26	30
Investments	22	15	13
Trade Receivables	274	314	698
Inventory	772	699	681
Other Assets	346	385	173
Total Assets	2362	2318	2415
Liabilities	2021	2022	2023
Share Capital	151.92	151.92	156.48
FV	10	10	10
Reserves	81	452	681
Borrowings	1139	856	850
Trade Payables	456	337	266
Other Liabilities	534.08	521.08	461.52
Total Liabilities	2362	2318	2415

Cash-Flow Statement			
Cash- Flow Statement	2021	2022	2023
PBT	-891	52	124.6
OPBWC	154	181.64	182.17
Change in Receivables	-12	-43	-384
Change in Inventories	30	73	18
Change in Payables	0	0	0
Other Changes	106	-96.12	226.32
Working Capital Change	124	-66.12	-139.68
Cash Generated From Operations	278	115.52	42.29
Tax	0	-0.18	0
Cash Flow From Operations	278	115.34	42.49
Purchase of PPE	-8	-16	2.4
Sale of PPE	0	0	0
Cash Flow From Investment	-8	-10.67	-1.39
Borrowing	-39	-6.8	-6.34
Divided	0	0	0
Equity	0	0	0
Others From Financing	-231	-98.33	-34.75
Cash Flow from Financing	-270	-105.13	-41.09
Net Cash Generated	0	-0.46	0.01
Cash at the Start	3	3	2.76
Cash at the End	3	2.54	2.77